Platelet content of nitric oxide synthase 3 phosphorylated at serine 1177 is associated with the functional response of platelets to aspirin

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Modrego, Javier ^a   Azcona, Luis ^a   Martín Palacios, Naiara ^a   Zamorano León, José J ^a   Segura, Antonio ^b   Rodríguez, Pablo ^a   Guerra, Reddy ^a   Tamargo, Juan ^a   Macaya, Carlos ^a   López Farré, Antonio J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Health Sciences Institute   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; COLLAGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GENOMIC DNA; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE; NITRITE; SERINE; ARGININE; N,N-DIMETHYLARGININE; NITRIC ACID DERIVATIVE; NOS2 PROTEIN, HUMAN; NOS3 PROTEIN, HUMAN; PHOSPHOSERINE;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; CELL LEVEL; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PLATELET REACTIVITY; PROTEIN CONTENT; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; ENZYMOLOGY; ERYTHROCYTE; FLOW CYTOMETRY; GENETICS; LEUKOCYTE; LIGHT; METABOLISM; MUTATION; PHOSPHORYLATION; THROMBOCYTE; WESTERN BLOTTING;

AGED; ARGININE; ASPIRIN; BLOOD PLATELETS; BLOTTING, WESTERN; COLLAGEN; ERYTHROCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKOCYTES; LIGHT; MALE; MUTATION; NITRATES; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; PHOSPHORYLATION; PHOSPHOSERINE;

EID: 84893412950     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082574     Document Type: Article

References (39)

1. Sase K, Michel T (1995) Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci 57: 2049-55.
2. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P (1995). Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med 125: 370-7.
3. Radomski MW, Palmer RM, Moncada S (1990). Characterization of the L-arginine: nitric oxide pathway in human platelets. Br J Pharmacol 101: 325-8. (Pubitemid 20292885)
4. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, et al (1997). Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100: 350-56. (Pubitemid 27349081)
5. Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JF Jr, et al (1998). Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation. 98: 1481-6. (Pubitemid 28481663)
6. Böger RH (2004). Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr.134: 2842S-47S.
7. Brunini T, Moss M, Siqueira M, Meirelles L, Rozentul A, et al (2004). Inhibition of l-arginine transport in platelets by asymmetric dimethylarginine and N-monomethyl-l-arginine: effects of arterial hypertension. Clin Exp Pharmacol Physiol. 31: 738-40. (Pubitemid 39540326)
8. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, et al (1999). T-786->C mutation in the 59-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation. 99: 2864-70. (Pubitemid 29258973)
9. Boo YC, Kim HJ, Song H, Fulton D, Sessa W, et al (2006). Coordinated regulation of endothelial nitric oxide synthase activity by phosphorylation and subcellular localization. Free Radic Biol Med. 411: 44-53.
10. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, et al (1999). Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 399: 601-5.
11. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, et al (2002). Aspirin-resistant, thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 105: 1650-5. (Pubitemid 34298607)
12. Grinstein J, Cannon CP (2012). Aspirin resistance: current status and role of tailored therapy. Clin Cardiol. 35: 673-81.
13. Mateos-Cáceres PJ, Macaya C, Azcona L, Modrego J, Mahillo E, et al (2010). Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients. Thromb Haemost. 103: 160-70.
14. Macchi L, Sorel N, Christiaens L (2006). Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Des. 12: 251-258.
15. Chakraborty K, Khan GA, Banerjee P, Ray U, Sinha AK (2003). Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Platelets 14: 421-27. (Pubitemid 38096113)
16. Reny JL, De Moerloose P, Dauzat M, Fontana P (2008). Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patient: a systematic review and meta-analysis. J Thromb Haemost. 6: 444-50. (Pubitemid 351280111)
17. López-Farré AJ, Mateos-Cáceres PJ, Sacristán D, Azcona L, Bernardo E, et al (2007). Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: a proteomic study. J Proteome Res. 6: 2481-7.
18. García-Cardoso J, Vela R, Mahillo E, Mateos-Cáceres PJ, Modrego J, et al (2010). Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction. Int J Impot Res. 22: 68-76.
19. Zamorano-León JJ, Alonso-Orgaz S, Moreno J, Cinza R, García-Torrent MJ, et al (2010). Novel mutation (H402R) in the S1 domain of KCNH2-encoded gene associated with long QT syndrome in a Spanish family. Int J Cardiol 142: 206-8.
20. Kawasaki T, Ozeki Y, Igawa T, Kambayashi J (2000). Increased platelet sensitivity to collagen in indivi duals resistant to low-dose aspirin. Stroke;31: 591-595. (Pubitemid 30131641)
21. López-Farré AJ, Caramelo C, Esteban A, Alberola ML, Millás I, et al (1995). Effects of Aspirin on platelet-neutrophil interactions: Role of nitric oxide and endothelin-1. Circulation 91;2080-2088.
22. McCabe TJ, Fulton D, Roman LJ, Sessa WC (2000). Enhanced electron flux and reduced calmodulin dissociation may explain "calcium-independent" eNOS activation by phosphorylation. J Biol Chem. 275: 6123-8. (Pubitemid 30129896)
23. Russo I, Doronzo G, Mattiello L, De Salve A, Trovati M, et al (2004). The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents. Thromb Res. 114: 265-273. (Pubitemid 39286012)
24. Leming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R (2001). Phosphorylation of Thr495 regulates Ca2+/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res. 88: 68-75.
25. Dosenko VE, Zagoriy VY, Lutay YM, Parkhomenko AN, Moibenko AA (2006). Allelic polymorphism in the promoter (T->C), but not in exon 7 (G->T) or the variable number tandem repeat in intron 4, of the endothelial nitric oxide synthase gene is positively associated with acute coronary syndrome in the Ukrainian population. Exp Clin Cardiol. 11: 11-3. (Pubitemid 43796466)
26. Cardaropoli S, Silvagno F, Morra E, Pescarmona GP, Todros T (2003). Infectious and inflammatory stimuli decrease endothelial nitric oxide synthase activity in vitro. J Hypertens. 21: 2103-10. (Pubitemid 38296872)
27. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997). Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men. N Engl J Med. 336: 973-9. (Pubitemid 27152782)
28. Ziegler S, Alt E, Brunner M, Speiser W, Minar E (2004). Influence of systemic inflammation on efficiency of antiplatelet therapy in PAOD patients. Ann Hematol 83: 92-4. (Pubitemid 38159611)
29. Homoncik M, Blann AD, Hollenstein U, Pernerstorfer T, Eichler HG, et al (2000). Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 111: 1250-2. (Pubitemid 32104947)
30. Vaziri ND,Wang XQ (1999). cGMP-mediated negative-feedback regulation of endothelial nitric oxide synthase expression by nitric oxide. Hypertension. 34: 1237-41.
31. Schedel A, Rolf N (2009). Genome-wide platelet RNA profiling in clinical samples. Methods Mol Biol. 496: 273-83.
32. Williams RH, Nollert MU (2004). Platelet-derived NO slows thrombus growth on a collagen type III surface. Thrombosis J 2: 11.
33. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR (2008). Aspirin «resistance» and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J. 336: 195-8. (Pubitemid 351212675)
34. Gambaryan S, Kobsar A, Hartmann S, Birschmann I, Kuhlencordt PJ, et al (2008). NO-synthase-/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity. J Thromb Haemost. 6: 1376-84. (Pubitemid 352016320)
35. Kang ES, Ford K, Grokulsky G, Wang YB, Chiang TM, et al (2000). Normal circulating adult human red blood cells contain inactive NOS proteins. J Lab Clin Med. 135: 444-451.
36. Böhmer A, Beckmann B, Sandmann J, Tsikas D (2012). Doubts concerning functional endothelial nitric oxide synthase in human erythrocytes. Blood. 119: 1322-1323.
37. López-Farré AJ, Zamorano-Leon JJ, Azcona L, Modrego J, Mateos-Cáceres PJ, et al (2011). Proteomic changes related to "bewildered" circulating platelets in the acute coronary syndrome. Proteomics. 11: 3335-48.
38. Chen LY, Mehta JL (1996). Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets. J Cardiovasc Pharmacol. 27: 154-8. (Pubitemid 26010653)
39. Ju H, Zou R, Venema VJ, Venema RC (1997). Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem. 272: 18522-5. (Pubitemid 27318186)